Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction.
Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction.
复制标题
急性心肌梗死患者和恢复期患者静脉注射和口服托卡尼可预防室性快速心律失常。
DOI：
10.1016/0002-8703(80)90205-7
复制
发表时间：
1980
影响因子：
4.8
通讯作者：
P. Smedgård
中科院分区：
文献类型：
--
作者：
L. Rydén;K. Arnman;T. Conradson;S. Hofvendahl;O. Mortensen;P. Smedgård
在一项双盲安慰剂对照研究中，对急性心肌梗死（AMI）患者给予托卡因胺，15分钟内直接静脉注射750毫克，随后口服800毫克，随后每日服用400毫克。在出现症状后尽快开始治疗；随访6个月。患者组包括56名服用托卡因胺的患者和56名服用安慰剂的患者。对心室颤动或症状性室性心动过速的发生率无显著影响。两组的死亡率相似且较低。托卡因胺抑制急性期和恢复期室性心律失常，包括室性心动过速。托卡因胺还能抑制运动性室性心律失常。副作用一般为轻度或中度。
In a double-blind placebo controlled study, tocainide, 750 mg i.v. during a 15-minute period directly followed by 800 mg orally and later 400 mg t.i.d., was administered to patients with acute myocardial infarction (AMI). Treatment was started as soon as possble following onset of symptoms; the follow-up period was 6 months. The patient groups consisted of 56 tocainide and 56 placebo patients. There was no significant effect on the incidence of ventricular fibrillation or symptomatic ventricular tachycardia. The mortality rates were similar and low in both groups. Tocainide suppressed ventricular arrhythmias, including ventricular tachycardia, both in the acute stage of AMI and during convalescence. Tocainide also suppressed exercise-induced ventricular arrhythmias. Side effects were in general mild or moderate.